View Item 

Show simple item record

Erythropoietin mediated bone formation is regulated by mTOR signaling
dc.contributor.authorKim, Jinkooen_US
dc.contributor.authorJung, Younghunen_US
dc.contributor.authorSun, Honglien_US
dc.contributor.authorJoseph, Jeenaen_US
dc.contributor.authorMishra, Anjalien_US
dc.contributor.authorShiozawa, Yusukeen_US
dc.contributor.authorWang, Jingchengen_US
dc.contributor.authorKrebsbach, Paul H.en_US
dc.contributor.authorTaichman, Russell S.en_US
dc.date.accessioned2012-01-05T22:07:03Z
dc.date.available2013-03-04T15:29:55Zen_US
dc.date.issued2012-01en_US
dc.identifier.citationKim, Jinkoo; Jung, Younghun; Sun, Hongli; Joseph, Jeena; Mishra, Anjali; Shiozawa, Yusuke; Wang, Jingcheng; Krebsbach, Paul H.; Taichman, Russell S. (2012). "Erythropoietin mediated bone formation is regulated by mTOR signaling." Journal of Cellular Biochemistry 113(1): 220-228. <http://hdl.handle.net/2027.42/89548>en_US
dc.identifier.issn0730-2312en_US
dc.identifier.issn1097-4644en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/89548
dc.description.abstractThe role of erythropoietin (Epo) and Epo/Epo receptor (EpoR) signaling pathways for production of red blood cells are well established. However, little is known about Epo/EpoR signaling in non‐hematopoietic cells. Recently, we demonstrated that Epo activates JAK/STAT signaling in hematopoietic stem cells (HSCs), leading to the production of bone morphogenetic protein 2 (BMP2) and bone formation and that Epo also directly activates mesenchymal cells to form osteoblasts in vitro. In this study, we investigated the effects of mTOR signaling on Epo‐mediated osteoblastogenesis and osteoclastogenesis. We found that mTOR inhibition by rapamycin blocks Epo‐dependent and ‐independent osteoblastic phenotypes in human bone marrow stromal cells (hBMSCs) and ST2 cells, respectively. Furthermore, we found that rapamycin inhibits Epo‐dependent and ‐independent osteoclastogenesis in mouse bone marrow mononuclear cells and Raw264.7 cells. Finally, we demonstrated that Epo increases NFATc1 expression and decreases cathepsin K expression in an mTOR‐independent manner, resulting in an increase of osteoclast numbers and a decrease in resorption activity. Taken together, these results strongly indicate that mTOR signaling plays an important role in Epo‐mediated bone homeostasis. J. Cell. Biochem. 113: 220–228, 2012. © 2011 Wiley Periodicals, Inc.en_US
dc.publisherWiley Subscription Services, Inc., A Wiley Companyen_US
dc.subject.otherOsteoblastsen_US
dc.subject.otherHSCsen_US
dc.subject.otherOsteoclastsen_US
dc.subject.otherErythropoietinen_US
dc.subject.otherMTORen_US
dc.subject.otherRapamycinen_US
dc.titleErythropoietin mediated bone formation is regulated by mTOR signalingen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelGeneticsen_US
dc.subject.hlbsecondlevelMolecular, Cellular and Developmental Biologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.subject.hlbtoplevelScienceen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDepartment of Periodontics and Oral Medicine, University of Michigan School of Dentistry, Ann Arbor, Michiganen_US
dc.contributor.affiliationumDepartment of Biologic and Materials Sciences, University of Michigan School of Dentistry, Ann Arbor, Michiganen_US
dc.contributor.affiliationumDepartment of Periodontics & Oral Medicine, University of Michigan School of Dentistry, 1011 North University Ave., Ann Arbor, MI 48109‐1078.en_US
dc.identifier.pmid21898543en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/89548/1/23347_ftp.pdf
dc.identifier.doi10.1002/jcb.23347en_US
dc.identifier.sourceJournal of Cellular Biochemistryen_US
dc.identifier.citedreferenceAcs G, Acs P, Beckwith SM, Pitts RL, Clements E, Wong K, Verma A. 2001. Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res 61: 3561 – 3565.en_US
dc.identifier.citedreferenceAnagnostou A, Lee ES, Kessimian N, Levinson R, Steiner M. 1990. Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc Natl Acad Sci USA 87: 5978 – 5982.en_US
dc.identifier.citedreferenceArcasoy MO. 2010. Non‐erythroid effects of erythropoietin. Haematologica 95: 1803 – 1805.en_US
dc.identifier.citedreferenceBab IA, Einhorn TA. 1993. Regulatory role of osteogenic growth polypeptides in bone formation and hemopoiesis. Crit Rev Eukaryot Gene Expr 3: 31 – 46.en_US
dc.identifier.citedreferenceBashutski JD, Eber RM, Kinney JS, Benavides E, Maitra S, Braun TM, Giannobile WV, McCauley LK. 2010. Teriparatide and osseous regeneration in the oral cavity. N Engl J Med 363: 2396 – 2405.en_US
dc.identifier.citedreferenceBianchi R, Buyukakilli B, Brines M, Savino C, Cavaletti G, Oggioni N, Lauria G, Borgna M, Lombardi R, Cimen B, Comelekoglu U, Kanik A, Tataroglu C, Cerami A, Ghezzi P. 2004. Erythropoietin both protects from and reverses experimental diabetic neuropathy. Proc Natl Acad Sci USA 101: 823 – 828.en_US
dc.identifier.citedreferenceBrager MA, Patterson MJ, Connolly JF, Nevo Z. 2000. Osteogenic growth peptide normally stimulated by blood loss and marrow ablation has local and systemic effects on fracture healing in rats. J Orthop Res 18: 133 – 139.en_US
dc.identifier.citedreferenceBrines M, Cerami A. 2005. Emerging biological roles for erythropoietin in the nervous system. Nat Rev Neurosci 6: 484 – 494.en_US
dc.identifier.citedreferenceCalvillo L, Latini R, Kajstura J, Leri A, Anversa P, Ghezzi P, Salio M, Cerami A, Brines M. 2003. Recombinant human erythropoietin protects the myocardium from ischemia‐reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci USA 100: 4802 – 4806.en_US
dc.identifier.citedreferenceCelik M, Gokmen N, Erbayraktar S, Akhisaroglu M, Konakc S, Ulukus C, Genc S, Genc K, Sagiroglu E, Cerami A, Brines M. 2002. Erythropoietin prevents motor neuron apoptosis and neurologic disability in experimental spinal cord ischemic injury. Proc Natl Acad Sci USA 99: 2258 – 2263.en_US
dc.identifier.citedreferenceDomracheva EV, Popova OI, Raimzhanov AR. 1985. Effect of high mountain altitude on the growth of bone marrow fibroblasts in patients with cytolytic syndromes. Ter Arkh 57: 40 – 42.en_US
dc.identifier.citedreferenceFlanagan AM. 1990. The osteoclast, which derives from a haemopoietic stem cell, is not depleted in aplastic anaemia. J Pathol 162: 261 – 263.en_US
dc.identifier.citedreferenceFoldes J, Naparstek E, Statter M, Menczel J, Bab I. 1989. Osteogenic response to marrow aspiration: Increased serum osteocalcin and alkaline phosphatase in human bone marrow donors. J Bone Miner Res 4: 643 – 646.en_US
dc.identifier.citedreferenceFrias MA, Thoreen CC, Jaffe JD, Schroder W, Sculley T, Carr SA, Sabatini DM. 2006. mSin1 is necessary for Akt/PKB phosphorylation, and its isoforms define three distinct mTORC2s. Curr Biol 16: 1865 – 1870.en_US
dc.identifier.citedreferenceGlantschnig H, Fisher JE, Wesolowski G, Rodan GA, Reszka AA. 2003. M‐CSF, TNFalpha and RANK ligand promote osteoclast survival by signaling through mTOR/S6 kinase. Cell Death Differ 10: 1165 – 1177.en_US
dc.identifier.citedreferenceGorio A, Gokmen N, Erbayraktar S, Yilmaz O, Madaschi L, Cichetti C, Di Giulio AM, Vardar E, Cerami A, Brines M. 2002. Recombinant human erythropoietin counteracts secondary injury and markedly enhances neurological recovery from experimental spinal cord trauma. Proc Natl Acad Sci USA 99: 9450 – 9455.en_US
dc.identifier.citedreferenceGrasso G, Sfacteria A, Cerami A, Brines M. 2004. Erythropoietin as a tissue‐protective cytokine in brain injury: What do we know and where do we go? Neuroscientist 10: 93 – 98.en_US
dc.identifier.citedreferenceHenke M, Mattern D, Pepe M, Bezay C, Weissenberger C, Werner M, Pajonk F. 2006. Do erythropoietin receptors on cancer cells explain unexpected clinical findings? J Clin Oncol 24: 4708 – 4713.en_US
dc.identifier.citedreferenceHong F, Larrea MD, Doughty C, Kwiatkowski DJ, Squillace R, Slingerland JM. 2008. mTOR‐raptor binds and activates SGK1 to regulate p27 phosphorylation. Mol Cell 30: 701 – 711.en_US
dc.identifier.citedreferenceInoki K, Li Y, Zhu T, Wu J, Guan KL. 2002. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 4: 648 – 657.en_US
dc.identifier.citedreferenceIsomoto S, Hattori K, Ohgushi H, Nakajima H, Tanaka Y, Takakura Y. 2007. Rapamycin as an inhibitor of osteogenic differentiation in bone marrow‐derived mesenchymal stem cells. J Orthop Sci 12: 83 – 88.en_US
dc.identifier.citedreferenceJacinto E, Loewith R, Schmidt A, Lin S, Ruegg MA, Hall A, Hall MN. 2004. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 6: 1122 – 1128.en_US
dc.identifier.citedreferenceJelkmann W, Bohlius J, Hallek M, Sytkowski AJ. 2008. The erythropoietin receptor in normal and cancer tissues. Crit Rev Oncol Hematol 67: 39 – 61.en_US
dc.identifier.citedreferenceKim DH, Sarbassov DD, Ali SM, King JE, Latek RR, Erdjument‐Bromage H, Tempst P, Sabatini DM. 2002. mTOR interacts with raptor to form a nutrient‐sensitive complex that signals to the cell growth machinery. Cell 110: 163 – 175.en_US
dc.identifier.citedreferenceLee MY, Fukunaga R, Lee TJ, Lottsfeldt JL, Nagata S. 1991. Bone modulation in sustained hematopoietic stimulation in mice. Blood 77: 2135 – 2141.en_US
dc.identifier.citedreferenceLee KW, Yook JY, Son MY, Kim MJ, Koo DB, Han YM, Cho YS. 2010. Rapamycin promotes the osteoblastic differentiation of human embryonic stem cells by blocking the mTOR pathway and stimulating the BMP/Smad pathway. Stem Cells Dev 19: 557 – 568.en_US
dc.identifier.citedreferenceLucas TS, Bab IA, Lian JB, Stein GS, Jazrawi L, Majeska RJ, Attar‐Namdar M, Einhorn TA. 1997. Stimulation of systemic bone formation induced by experimental blood loss. Clin Orthop Relat Res 340: 267 – 275.en_US
dc.identifier.citedreferenceMartin SK, Fitter S, Bong LF, Drew JJ, Gronthos S, Shepherd PR, Zannettino AC. 2010. NVP‐BEZ235, a dual pan class I PI3 kinase and mTOR inhibitor, promotes osteogenic differentiation in human mesenchymal stromal cells. J Bone Miner Res 25: 2126 – 2137.en_US
dc.identifier.citedreferenceMasuda S, Nagao M, Takahata K, Konishi Y, Gallyas F, Jr., Tabira T, Sasaki R. 1993. Functional erythropoietin receptor of the cells with neural characteristics. Comparison with receptor properties of erythroid cells. J Biol Chem 268: 11208 – 11216.en_US
dc.identifier.citedreferenceMogi M, Kondo A. 2009. Down‐regulation of mTOR leads to up‐regulation of osteoprotegerin in bone marrow cells. Biochem Biophys Res Commun 384: 82 – 86.en_US
dc.identifier.citedreferenceNiziolek PJ, Murthy S, Ellis SN, Sukhija KB, Hornberger TA, Turner CH, Robling AG. 2009. Rapamycin impairs trabecular bone acquisition from high‐dose but not low‐dose intermittent parathyroid hormone treatment. J Cell Physiol 221: 579 – 585.en_US
dc.identifier.citedreferenceNojima H, Tokunaga C, Eguchi S, Oshiro N, Hidayat S, Yoshino K, Hara K, Tanaka N, Avruch J, Yonezawa K. 2003. The mammalian target of rapamycin (mTOR) partner, raptor, binds the mTOR substrates p70 S6 kinase and 4E‐BP1 through their TOR signaling (TOS) motif. J Biol Chem 278: 15461 – 15464.en_US
dc.identifier.citedreferencePhornphutkul C, Lee M, Voigt C, Wu KY, Ehrlich MG, Gruppuso PA, Chen Q. 2009. The effect of rapamycin on bone growth in rabbits. J Orthop Res 27: 1157 – 1161.en_US
dc.identifier.citedreferenceRichmond TD, Chohan M, Barber DL. 2005. Turning cells red: Signal transduction mediated by erythropoietin. Trends Cell Biol 15: 146 – 155.en_US
dc.identifier.citedreferenceSanchez CP, He YZ. 2009. Bone growth during rapamycin therapy in young rats. BMC Pediatr 9: 3.en_US
dc.identifier.citedreferenceSarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF, Markhard AL, Sabatini DM. 2006. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 22: 159 – 168.en_US
dc.identifier.citedreferenceShiozawa Y, Jung Y, Ziegler AM, Pedersen EA, Wang J, Wang Z, Song J, Lee CH, Sud S, Pienta KJ, Krebsbach PH, Taichman RS. 2010. Erythropoietin couples hematopoiesis with bone formation. PLoS ONE 5: e10853.en_US
dc.identifier.citedreferenceShoba LN, Lee JC. 2003. Inhibition of phosphatidylinositol 3‐kinase and p70S6 kinase blocks osteogenic protein‐1 induction of alkaline phosphatase activity in fetal rat calvaria cells. J Cell Biochem 88: 1247 – 1255.en_US
dc.identifier.citedreferenceSingbrant S, Russell MR, Jovic T, Liddicoat B, Izon DJ, Purton LE, Sims NA, Martin TJ, Sankaran VG, Walkley CR. 2011. Erythropoietin couples erythropoiesis, B‐lymphopoiesis, and bone homeostasis within the bone marrow microenvironment. Blood 117: 5631 – 5642.en_US
dc.identifier.citedreferenceSingha UK, Jiang Y, Yu S, Luo M, Lu Y, Zhang J, Xiao G. 2008. Rapamycin inhibits osteoblast proliferation and differentiation in MC3T3‐E1cells and primary mouse bone marrow stromal cells. J Cell Biochem 103: 434 – 446.en_US
dc.identifier.citedreferenceSmink JJ, Begay V, Schoenmaker T, Sterneck E, de Vries TJ, Leutz A. 2009. Transcription factor C/EBPbeta isoform ratio regulates osteoclastogenesis through MafB. EMBO J 28: 1769 – 1781.en_US
dc.identifier.citedreferenceSugatani T, Hruska KA. 2005. Akt1/Akt2 and mammalian target of rapamycin/Bim play critical roles in osteoclast differentiation and survival, respectively, whereas Akt is dispensable for cell survival in isolated osteoclast precursors. J Biol Chem 280: 3583 – 3589.en_US
dc.identifier.citedreferenceSzenajch J, Wcislo G, Jeong JY, Szczylik C, Feldman L. 2010. The role of erythropoietin and its receptor in growth, survival and therapeutic response of human tumor cells From clinic to bench—A critical review. Biochim Biophys Acta 1806: 82 – 95.en_US
dc.identifier.citedreferenceVander Haar E, Lee SI, Bandhakavi S, Griffin TJ, Kim DH. 2007. Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40. Nat Cell Biol 9: 316 – 323.en_US
dc.identifier.citedreferenceYamaji R, Okada T, Moriya M, Naito M, Tsuruo T, Miyatake K, Nakano Y. 1996. Brain capillary endothelial cells express two forms of erythropoietin receptor mRNA. Eur J Biochem 239: 494 – 500.en_US
dc.identifier.citedreferenceYazigi A, Maalouf G, Inati‐Khoriati A, Tamim H, Saab C. 2002. Bone mineral density in beta‐thalassemic Lebanese children. J Musculoskelet Neuronal Interact 2: 463 – 468.en_US
dc.identifier.citedreferenceZoncu R, Efeyan A, Sabatini DM. 2011. mTOR: From growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 12: 21 – 35.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
23347_ftp.pdf
Size:
1.281MB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.